€15M Seed Raised by Cure51: Unraveling the Enigma of Cancer Survival
Rather than grimly assembling data about cancer deaths to predict outcomes in treatment, the founders of Cure51 had another idea.
Instead, the company assembles data about long term survivors of cancer, thus hoping to crack the code on what keeps people alive.
It’s now raised a €15 million Seed round led by Paris-based Sofinnova Partners.
Other investors in this round included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
Both had previously worked in five well-known oncology centers, such as the Gustave Roussy Institute in Paris and the Vall d’Hebronin Barcelona.
